Abstract
Matrix metalloproteinases (MMPs) were postulated to have important implication in progression and invasiveness of many malignant disorders. On the other hand the biological role of MMP‐2 in acute myeloid leukaemia (AML) is not fully clear. Serum samples from 37 adult patients with AML had been taken before chemotherapy was administered. In addition 20 out of the 37 patients were analysed again after achieving complete remission (CR). Ten samples from healthy volunteers were evaluated as the control. Total MMP‐2 levels were measured using ELISA Kit obtained from R&D system. MMP‐2 serum levels were significantly lower in pretreatment AML patients than that in the normal controls (p = 0.000) and in CR (p = 0.007). No significant correlations were detected between pretreatment sMMP‐2 levels and FAB subtypes, peripheral blood blast cell counts, peripheral blood WBCs, bone marrow blast cell counts or blast cell distribution ratio. The prognostic value of MMP‐2 was evaluated by dividing AML patients into high and low MMP‐2 groups using the pretreatment median MMP‐2 level of the AML group as the cut‐off. The authors found that patients in the high group survived for a significantly shorter time than those patients in the lower MMP‐2 group. High pretreatment levels of sMMP‐2 among AML patients were associated with poor survival. Prospective studies are recommended to establish the clinical value of longitudinal sMMP‐2 measurement. Copyright © 2007 John Wiley & Sons, Ltd.